Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Recruiting now · Phase 1/Phase 2
Conditions studied: Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
In brief
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV, and EBV, in subjects who have previously received any type of allogeneic HCT or solid organ transplant (SOT), or have compromised immunity. Reconstitution of anti-viral immunity by donor-derived cytotoxic T lymphocytes has shown promise in preventing and treating infections with adenovirus, CMV, and EBV. However, the weeks taken to prepare patient-specific products, and cost associated with products that may not be used limits their value. In this trial, we will evaluate viral specific T cells generated by gamma capture technology. Eligible patients will include HCT and/or SOT recipients, and/or patients with compromised immunity who have adenovirus, CMV, or EBV infection or refractory viremia that is persistent despite standard therapy. Infusion of the cellular product will be assessed for safety and efficacy.
Key facts
- Study ID
- NCT06909110
- Run by
- Jessie L. Alexander
- People needed
- 25
- Starts
- 2025-04-30
- Expected to finish
- 2032-01-01
- Last updated by the study team
- 2025-08-14
Who can join
Age: 0 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lucile Packard Children's Hospital — Palo Alto, California, United States (enrolling)
- Lucile Packard Children's Hospital — Palo Alto, California, United States (enrolling)
- Jessie Alexander — Palo Alto, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.